Form 4: Fennec Pharma Director Sells Shares Under 10b5-1 Plan

Fennec Pharmaceuticals Director Rosty Raykov sold 10,000 common shares for $8.10 each, reducing his direct beneficial ownership to 82,318 shares.

Summary

• Rosty Raykov, a Director of FENNEC PHARMACEUTICALS INC. (FENC), reported a sale of common shares.
• The transaction involved the disposition of 10,000 common shares.
• The shares were sold at a price of $8.10 per share.
• The sale occurred on November 5, 2025.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was dated August 23, 2024.
• Following this transaction, Rosty Raykov directly beneficially owns 82,318 common shares of Fennec Pharmaceuticals.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a pre-planned sale under a 10b5-1 plan, which is a common practice for insiders to manage personal finances and does not necessarily indicate a change in confidence in the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing details a routine, pre-planned insider transaction by a director, which is a common occurrence across all industries for liquidity or diversification purposes and does not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale by a director, while pre-planned, represents a minor reduction in insider ownership. Given it's a 10b5-1 plan, the impact on market sentiment is typically minimal compared to an unplanned open-market sale.

Key Dates

Keywords

Fennec Pharmaceuticals, FENC, Rosty Raykov, Director, Insider Trading, Form 4, Share Sale, 10b5-1 Plan, Beneficial Ownership